Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial
Gebhart, G., Lamberts, L.E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M., Aftimos, P., Tol, J., Oyen, W.J.G., Vugts, D.J., Hoekstra, O.S., Schröder, C.P., Menke-van derLanguage:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv577
Date:
November, 2015
File:
PDF, 742 KB
english, 2015
File converter
More search results
More benefits 
